Ticker Details
Verastem, Inc. Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
IPO Date:	February 1, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$623.98M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.93%
Avg Daily Range (30 D):	$0.21 | 3.37%
Avg Daily Range (90 D):	$0.19 | 3.55%

Institutional Daily Volume
Avg Daily Volume:	1.28M
Avg Daily Volume (30 D):	1.84M
Avg Daily Volume (90 D):	2.09M

Trade Size
Avg Trade Size (Sh.):	236
Avg Trade Size (Sh.) (30 D):	100
Avg Trade Size (Sh.) (90 D):	117

Institutional Trades
Total Institutional Trades:	1,003
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$1.69M
Avg Institutional Trade (90 D):	$1.63M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.77M
Avg Closing Trade (30 D):	$1.82M
Avg Closing Trade (90 D):	$1.65M
Avg Closing Volume:	174.37K

News

Nov 12, 2025 @ 6:00 PM KRAS Inhibitors Market to Witness Explosive Growth... Source: Delveinsight

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Mar 8, 2025 @ 12:33 PM Why the Global Cancer Market Could Surpass $900 Bi... Source: Prnewswire

Jul 24, 2024 @ 9:27 AM Why Enphase Energy Shares Are Trading Higher; Here... Source: Avi Kapoor

Jul 10, 2024 @ 6:51 PM Verastem, Inc. Investors: Company Investigated by ... Source: N/A

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.36	$-.35	$-.37
Diluted EPS	$-2.45	$-.35	$-.46
Revenue	$87.53M	$40.08M	$18.67M
Gross Profit
Net Income / Loss	$-202.7M	$-34.67M	$-36.59M
Operating Income / Loss	$-159.8M	$-32.71M	$-44.9M
Cost of Revenue
Net Cash Flow	$47.54M	$-29.2M	$-39.44M
PE Ratio

Splits
Jun 01, 2023	1:12